How to Assess Experimental Vaccine Use During an Ebola Outbreak: A Step-by-Step Guide

Introduction

When a new Ebola outbreak emerges, the first line of defense is often vaccination. But what happens when the outbreak is caused by a strain for which no approved vaccine exists? That is precisely the challenge facing health officials in the Democratic Republic of the Congo (DRC), where the latest Ebola outbreak—already the fourth largest on record—is spreading in a conflict-ridden region. The culprit is the Bundibugyo species of Ebola, for which there is no licensed vaccine. However, a sliver of scientific evidence suggests that Merck’s Ervebo, designed for a different species (Zaire ebolavirus), might offer some cross-protection. This guide outlines how experts can weigh the use of such an ad hoc measure, step by step, while navigating logistical, ethical, and scientific hurdles.

What You Need

• Epidemiological data – Confirmed case counts, geographic spread, and transmission patterns.
• Laboratory capacity – Ability to identify the specific Ebola species (e.g., PCR sequencing).
• Existing vaccine documentation – Full prescribing information, clinical trial results, and post-marketing safety data for Ervebo.
• Cross-protection studies – Peer-reviewed research, animal model results, and any human immunogenicity data for Bundibugyo.
• Ethical review board – A body to evaluate emergency use authorization.
• Conflict zone security assessment – Risk of violence impacting vaccination teams.
• Cold chain logistics – Equipment to store Ervebo at -80°C (or -20°C depending on formulation).
• Community engagement plan – Strategies to gain trust and consent in a sensitive region.

Step-by-Step Guide

Step 1: Confirm the Ebola Species

Before considering any vaccine, you must positively identify the virus. Use RT-PCR or sequencing from patient samples to confirm it’s Bundibugyo ebolavirus. This step is critical because Ervebo is designed for the Zaire species, and cross-reactivity is not guaranteed. Without confirmation, the entire evaluation is baseless.

Step 2: Review Licensed Vaccines and Their Targets

Compile a list of all WHO-prequalified Ebola vaccines. Currently, only Merck’s Ervebo (for Zaire ebolavirus) is licensed. Also note Johnson & Johnson’s Zabdeno/Mvabea regimen (also for Zaire). Document their mechanisms: Ervebo is a live-attenuated recombinant vesicular stomatitis virus (rVSV) vector carrying the glycoprotein of Zaire. Identify any structural similarities between the Bundibugyo and Zaire glycoproteins.

Step 3: Evaluate Cross-Protection Evidence

Search the scientific literature for studies that test Ervebo or similar rVSV vaccines against Bundibugyo in animal models. For example, some non-human primate studies showed that a Zaire-based vaccine provided partial protection against Bundibugyo challenge. Review human immunogenicity data of Ervebo in previous outbreaks—does it generate antibodies that cross-neutralize Bundibugyo in vitro? A 2021 study in Nature Communications indicated that sera from Ervebo-vaccinated individuals had some cross-neutralizing activity against Bundibugyo. This is the “tiny bit of evidence” mentioned. Document the strength and limitations.

Step 4: Weigh Risks and Benefits in a Conflict Zone

The DRC outbreak is in a conflict zone where containment is challenging. The risk of using an unproven vaccine includes potential lack of efficacy, waste of resources, erosion of trust if the vaccine fails, and side effects. The benefit, however, is the chance to stop transmission when no other vaccine exists. Calculate the risk-benefit ratio: if the estimated case fatality rate for Bundibugyo is high (35–40%), and if the vaccine is safe, even modest efficacy might be worth the attempt. Consult with military and humanitarian teams to assess security for vaccine deployment.

Step 5: Obtain Emergency Use Authorization (EUA) or Ethics Approval

Given the urgency, you cannot wait for full clinical trials. Seek an EUA from the DRC’s ethics committee and the WHO. Present the cross-protection evidence, manufacturing quality data, and a plan for informed consent. The approval process should include independent experts who can challenge assumptions. Document the decision-making process publicly to maintain transparency.

Step 6: Implement a Controlled Vaccination Strategy

Do not vaccinate blindly. Use a ring vaccination approach—vaccinating contacts of confirmed cases, as was done in the 2014–16 West Africa outbreak. This strategy maximizes the chance of detecting an effect while conserving doses. Prioritize healthcare workers and vulnerable individuals. Because this is a long shot, integrate rigorous data collection: track adverse events, breakthrough infections, and antibody levels before and after vaccination.

Step 7: Monitor Outcomes and Adapt

Set up a real-time surveillance system. Compare infection rates in vaccinated vs. unvaccinated rings (if ethical, use a stepped-wedge design). If after a few weeks the vaccine shows no effect—or worse, appears harmful—discontinue use immediately. If partial protection is observed, expand the campaign and inform the global community. The data will inform future outbreak responses.

Conclusion & Tips

Using an unapproved vaccine during an outbreak is a high-stakes decision. This guide provides a structured approach, but the reality is messy. Key takeaways:

• Never skip species identification – Misidentification leads to wasted effort.
• Build on existing data – Even weak cross-protection evidence can be a starting point.
• Involve the community – Misinformation in conflict zones can doom a campaign. Use local leaders to communicate uncertainties.
• Plan for failure – Have a contingency if the vaccine doesn’t work. Continue other interventions (contact tracing, isolation, safe burials).
• Share results openly – Publish outcomes, whether positive or negative, to help others facing similar dilemmas.

Ultimately, the decision to deploy an experimental vaccine like Ervebo against Bundibugyo must balance science, ethics, and logistics. While a long shot, it may be the best shot available.